Clinical Trial Update: Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the pharmacokinetics, safety, and tolerability of TPM XR as adjunctive therapy in pediatric epilepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Qudexy XR (topiramate extended-release)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Epilepsy | Phase 1, Phase 2 | Status: COMPLETED